Education
About Us
Working with TipRanks
Follow Us
Sight Sciences (SGHT)
NASDAQ:SGHT
Earnings Data
Report Date
May 13, 2026After Close (Confirmed)
Period Ending
2026 (Q1)Consensus EPS Forecast
-0.16Last Year’s EPS
-0.28Same Quarter Last Year
Moderate Buy
Based on 8 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call conveyed constructive operational momentum: revenue growth (+7% Q4), strong 87% gross margins, meaningful operating expense reductions (total OpEx -25%, adjusted OpEx -23%), narrowing net loss, and a major reimbursement milestone (two MACs) enabling a reimbursed TearCare launch. Management provided prudent 2026 guidance ($82M–$88M) that anticipates growth in both Interventional Glaucoma and a scaled Interventional Dry Eye business ($5M–$7M), while also planning targeted commercial and market-access investments. Key risks remain: TearCare is still early-stage and dependent on additional payer wins and commercial scale, cash declined year-over-year and the company remains GAAP-loss-making, and potential future reimbursement code changes (goniotomy) could pressure aspects of the glaucoma market. Overall, positive execution and clear growth initiatives outweigh the remaining operational and reimbursement risks, but realization of the upside depends on successful market access and scaling execution.Company Guidance
Total Revenue Growth
Q4 total revenue was $20.4M, up 7% year-over-year, driven by strength in Interventional Glaucoma and early traction in Interventional Dry Eye.
Interventional Glaucoma Performance
Interventional Glaucoma revenue was $19.7M, up 5% year-over-year and flat sequentially; ordering accounts increased ~2% year-over-year and utilization remained healthy with higher Omni Edge usage driving higher average selling prices.
Interventional Dry Eye Commercial Momentum & Reimbursement Milestone
Interventional Dry Eye revenue reached $0.7M in Q4 (vs $0.3M prior year). Two MACs (Novitas and First Coast) established CPT 0563T pricing for TearCare, enabling a reimbursed business model. Q4 sales included ~700 SmartLids to ~80 accounts (about 30 new accounts).
Very Strong Gross Margins
Company-wide gross margin was 87% (consistent with prior year). Interventional Glaucoma gross margin improved to 88% (from 87%) and Interventional Dry Eye gross margin improved to 68% (from 51%), driven by higher average selling prices and favorable product mix.
Operating Expense Discipline and Reduced Loss
Total operating expenses fell 25% year-over-year to $21.5M and adjusted operating expenses fell 23% to $18.9M following an August 2025 reduction in force. Net loss narrowed to $4.2M ($0.08/sh) from $11.8M ($0.23/sh) year-over-year.
Strong Cash Management and Low Cash Usage
Cash and cash equivalents ended Q4 at $92M (down from $120.4M at end of 2024). Quarterly cash usage was only $0.4M—the lowest cash-usage quarter of the year—supporting management’s view of operating discipline and path toward cash flow breakeven without additional equity.
2026 Revenue Guidance and Growth Target
Management initiated full-year 2026 revenue guidance of $82M–$88M (6%–14% growth vs. 2025). Guidance splits include Interventional Glaucoma $77M–$81M (2%–7% growth) and Interventional Dry Eye $5M–$7M (vs $1.6M prior year), reflecting expected ramp of reimbursed TearCare.
Focused Commercial Investments to Scale
Company intends targeted market access and commercial investments in 2026—particularly to scale reimbursed Interventional Dry Eye and to develop the underpenetrated stand-alone Interventional Glaucoma market—while maintaining financial discipline.
SGHT Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
SGHT Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Mar 04, 2026 | $5.41 | $3.96 | -26.80% |
Nov 06, 2025 | $5.00 | $5.82 | +16.40% |
Aug 07, 2025 | $3.55 | $4.24 | +19.44% |
May 08, 2025 | $3.03 | $3.08 | +1.65% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Sight Sciences (SGHT) report earnings?
Sight Sciences (SGHT) is schdueled to report earning on May 13, 2026, After Close (Confirmed).
What is Sight Sciences (SGHT) earnings time?
Sight Sciences (SGHT) earnings time is at May 13, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is SGHT EPS forecast?
SGHT EPS forecast for the fiscal quarter 2026 (Q1) is -0.16.